Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Moses KA, Orom H, Brasel A, Gaddy J, Underwood W 3rd.

Urology. 2017 Jan;99:76-83. doi: 10.1016/j.urology.2016.07.045.

PMID:
27667157
2.

Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.

Moses KA, Orom H, Brasel A, Gaddy J, Underwood W 3rd.

Urol Oncol. 2016 Sep;34(9):415.e7-415.e12. doi: 10.1016/j.urolonc.2016.04.002.

PMID:
27161898
3.

Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.

Schmid M, Meyer CP, Reznor G, Choueiri TK, Hanske J, Sammon JD, Abdollah F, Chun FK, Kibel AS, Tucker-Seeley RD, Kantoff PW, Lipsitz SR, Menon M, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Jan;2(1):85-93. doi: 10.1001/jamaoncol.2015.3384.

4.

Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy.

Moses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA.

BMC Urol. 2014 Dec 11;14:98. doi: 10.1186/1471-2490-14-98.

5.

Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Murphy AB, Bhatia R, Martin IK, Klein DA, Hollowell CM, Nyame Y, Dielubanza E, Achenbach C, Kittles RA.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2009-18. doi: 10.1158/1055-9965.EPI-14-0614.

6.

Life-Threatening Disparities: The Treatment of Black and White Cancer Patients.

Penner LA, Eggly S, Griggs JJ, Underwood W 3rd, Orom H, Albrecht TL.

J Soc Issues. 2012 Jun 25;68(2). doi: 10.1111/j.1540-4560.2012.01751.x.

7.
8.

Racial/ethnic differences in treatment discussed, preferred, and received for prostate cancer in a tri-ethnic population.

Hosain GM, Sanderson M, Du XL, Chan W, Strom SS.

Am J Mens Health. 2012 May;6(3):249-57. doi: 10.1177/1557988311432467.

9.

Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.

Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood W 3rd.

Cancer. 2011 Oct 15;117(20):4651-8. doi: 10.1002/cncr.26103.

10.

Access to hematopoietic stem cell transplantation: effect of race and sex.

Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM.

Cancer. 2010 Jul 15;116(14):3469-76. doi: 10.1002/cncr.25297.

11.

Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E.

BMC Cancer. 2010 Apr 19;10:152. doi: 10.1186/1471-2407-10-152.

12.

Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.

Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA.

J Clin Oncol. 2010 Feb 20;28(6):1069-74. doi: 10.1200/JCO.2009.26.2469.

13.

Race, healthcare access and physician trust among prostate cancer patients.

Do YK, Carpenter WR, Spain P, Clark JA, Hamilton RJ, Galanko JA, Jackman A, Talcott JA, Godley PA.

Cancer Causes Control. 2010 Jan;21(1):31-40. doi: 10.1007/s10552-009-9431-y.

14.

Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer.

Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Kaijun Liao, Schwartz JS, Pollack CE, Wong YN, Armstrong K.

Med Care Res Rev. 2009 Aug;66(4):409-35. doi: 10.1177/1077558709333996.

15.

The contribution of cancer incidence, stage at diagnosis and survival to racial differences in years of life expectancy.

Wong MD, Ettner SL, Boscardin WJ, Shapiro MF.

J Gen Intern Med. 2009 Apr;24(4):475-81. doi: 10.1007/s11606-009-0912-1.

16.

Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes.

Zeigler-Johnson CM, Spangler E, Jalloh M, Gueye SM, Rennert H, Rebbeck TR.

Can J Urol. 2008 Feb;15(1):3872-82. Review.

17.

Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients.

Oakley-Girvan I, Kolonel LN, Gallagher RP, Wu AH, Felberg A, Whittemore AS.

Am J Public Health. 2003 Oct;93(10):1753-9.

18.

Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, Potosky AL.

J Gen Intern Med. 2003 Oct;18(10):845-53.

19.

Changes in radical prostatectomy and radiation therapy rates for African Americans and whites.

Shaw M, Elterman L, Rubenstein M, McKiel CF, Guinan P.

J Natl Med Assoc. 2000 Jun;92(6):281-4.

20.

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.

Bergan RC, Walls RG, Figg WD, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E.

J Natl Med Assoc. 1997 Sep;89(9):622-8.

Items per page

Supplemental Content

Support Center